# A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

Study · id `cardio:ct-nct03897868` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03897868](<https://clinicaltrials.gov/study/NCT03897868>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03897868

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.

## Technical summary

Registry record NCT03897868. Randomized; double masking; primary purpose treatment. Start 2019-03-21 (actual); primary completion 2020-02-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 248 participants (enrolled count; ClinicalTrials.gov record NCT03897868, source copy `cardio:ctgov-nct03897868-2022-07-14`, retrieved 2026-10-26)
- Started: 2019-03-21 (actual) (ClinicalTrials.gov record NCT03897868, source copy `cardio:ctgov-nct03897868-2022-07-14`, retrieved 2026-10-26)
- Primary completion: 2020-02-26 (actual) (ClinicalTrials.gov record NCT03897868, source copy `cardio:ctgov-nct03897868-2022-07-14`, retrieved 2026-10-26)
- Completion: 2020-02-26 (actual) (ClinicalTrials.gov record NCT03897868, source copy `cardio:ctgov-nct03897868-2022-07-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03897868, source copy `cardio:ctgov-nct03897868-2022-07-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03897868-2022-07-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
- Acronym: HM\_APOLLO
- Condition: Hypertension
- Intervention (Drug): HCP1803
- Intervention (Drug): Amlodipine
- Intervention (Drug): Losartan
- Intervention (Drug): Placebo
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)
- Registry intervention name matches this record: Losartan (`cardio:losartan`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: 1436808dd24f7f10a2ad943f531d272211908bad99a0c4b2a11c9c73d97d67a1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
